<DOC>
	<DOC>NCT02615002</DOC>
	<brief_summary>This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.</brief_summary>
	<brief_title>Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient and caregiver are willing to take part in the entire study Signed informed consent from the patient and the caregiver Patient has a clearly documented history either in medical records or from an informant of cognitive decline over at least 6 months Patient has mild probable AD as consistent with criteria established by the NIAAA CT/MRI scan with finding consisted with probable AD obtained during the last 12 months before Screening Patient has an MMSE score of 2126 (inclusive) at Screening Patient has a Clinical Dementia Rating Global Score (CDRGS) of 0.51 (mild dementia) at Screening Patients receiving prescribed drugs for treatment of AD including acetyl cholinesterase inhibitors [eg, donepezil, galantamine, rivastigmine] should be on a stable dose for at least 3 months before Screening Patient has a negative drug screen (benzodiazepines or opiates) at Screening Female patients must have had last natural menstruation â‰¥ 24 months before Screening, OR be surgically sterile Male patients must agree to use of effective contraception if female partner is of childbearing potential, OR be surgically sterile Patient has an alternative cause for dementia other than AD as determined by CT or MRI scan Patient has evidence of any clinically significant neurodegenerative disease Patient has been diagnosed with the following Axis I disorders (DSM V criteria) Patient has a history of uncontrolled or untreated cardiovascular, endocrine, gastrointestinal, respiratory, or rheumatologic disorders within the past 5 years Patient has severe pain that is likely to interfere with sleep Continuous use of benzodiazepines or other sedativehypnotics during the 2 weeks before Screening Use of any kind of melatonin/melatonin agonist during the 2 weeks before Screening Patient has known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists Patients with an irregular lifestyle or life pattern (eg, shift workers, patients likely to be jet lagged).</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cognition</keyword>
	<keyword>mild Alzheimer's disease</keyword>
	<keyword>Sleep</keyword>
</DOC>